REFERENCES
- Hake S B, Xiao A, Allis C D. Linking the epigenetic ‘language’ of covalent histone modifications to cancer. Br J Cancer. 2004; 90: 761–9. [PUBMED], [INFOTRIEVE]
- Egger G L, Aparicio A, Jones P A. Epigenetics in human disease and prospects for epigenetic therapy. Nature. 2004; 429: 457–63. [PUBMED], [INFOTRIEVE]
- Feinberg A P, Tycko B. The history of cancer epigenetics. Nat Rev Cancer. 2004; 4: 143–53. [PUBMED], [INFOTRIEVE]
- Moggs J G, Goodman J I, Trosko J E, Roberts R A.. Epigenetics and cancer: Implications for drug discovery and safety assessment. Toxicol Appl Pharmacol. 2004; 196: 422–30. [PUBMED], [INFOTRIEVE]
- Eads C A, Lord R V, Wickramasinghe K, Long T I, Kurumboor S K, Bernstein L, Peters J H, DeMeester S R, DeMeester T R, Skinner K A, Laird P W. Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res. 2001; 61: 3410–8. [PUBMED], [INFOTRIEVE]
- Kim K C, Geng L, Huang S. Inactivation of a histone methyltransferase by mutations in human cancers. Cancer Res. 2003; 63: 7619–23. [PUBMED], [INFOTRIEVE]
- Peters A H, Scherthan H, Mechtler K, Sauer S, Schofer C, Weipoltshammer K, Pagani M, Lachner M, Kohlmaier A, Opravil S, Doyle M, Sibilia M, Jenuwein T. Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability. Cell. 2001; 107: 323–37. [PUBMED], [INFOTRIEVE]
- Villar-Garea A, Esteller M. DNA demethylating agents and chromatin-remodelling drugs: Which, how and why?. Curr Drug Metab. 2003; 4: 11–31. [PUBMED], [INFOTRIEVE]
- Johnstone R W, Licht J D. Histone deacetylase inhibitors in cancer therapy: Is transcription the primary target?. Cancer Cell. 2003; 4: 13–8. [PUBMED], [INFOTRIEVE]
- Marks P A, Richon V M, Rifkind R A. Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst. 2000; 92: 1210–6. [PUBMED], [INFOTRIEVE]
- Costa M, Klein C B. Nickel carcinogenesis, mutation, epigenetics, or selection. Environ Health Perspect. 1999; 107: A438–9. [PUBMED], [INFOTRIEVE]
- Breivik J, Gaudernack G. Genomic instability, DNA methylation, and natural selection in colorectal carcinogenesis. Semin Cancer Biol. 1999; 9: 245–54. [PUBMED], [INFOTRIEVE]
- Breivik J, Gaudernack G.. Carcinogenesis and natural selection: A new perspective to the genetics and epigenetics of colorectal cancer. Adv Cancer Res. 1999; 76: 187–212. [PUBMED], [INFOTRIEVE]
- Singh S M, Murphy B, O'Reilly R L. Involvement of gene-diet/drug interaction in DNA methylation and its contribution to complex diseases: From cancer to schizophrenia. Clin Genet. 2003; 64: 451–60. [PUBMED], [INFOTRIEVE]
- Laird P W, Jaenisch R. The role of DNA methylation in cancer genetic and epigenetics. Annu Rev Genet. 1996; 30: 441–64. [PUBMED], [INFOTRIEVE]
- Verma M, Dunn B K, Ross S, Jain P, Wang W, Hayes R, Umar A. Early detection and risk assessment: Proceedings and recommendations from the Workshop on Epigenetics in Cancer Prevention. Ann NY Acad Sci. 2003; 983: 298–319. [PUBMED], [INFOTRIEVE]
- Liang G, Chan M F, Tomigahara Y, Tsai Y C, Gonzales F A, Li E, Laird P W, Jones P A. Cooperativity between DNA methyltransferases in the maintenance methylation of repetitive elements. Mol Cell Biol. 2002; 22: 480–91. [PUBMED], [INFOTRIEVE]
- Costello J F, Fruhwald M C, Smiraglia D J, Rush L J, Robertson G P, Gao X, Wright F A, Feramisco J D, Peltomaki P, Lang J C, Schuller D E, Yu L, Bloomfield C D, Caligiuri M A, Yates A, Nishikawa R, Su Huang H, Petrelli N J, Zhang X, O'Dorisio M S, Held W A, Cavenee W K, Plass C. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet. 2000; 24: 132–8. [PUBMED], [INFOTRIEVE]
- Jabs E W, Goble C A, Cutting G R. Macromolecular organization of human centromeric regions reveals high-frequency, polymorphic macro DNA repeats. Proc Natl Acad Sci USA. 1989; 86: 202–6. [PUBMED], [INFOTRIEVE]
- Kiyama R, Oishi M, Kanda N. Cytoplasmic localization of human repetitive DNA revealed by in situ hybridization. Exp Cell Res. 1989; 183: 239–44. [PUBMED], [INFOTRIEVE]
- Strichman-Almashanu L Z, Lee R S, Onyango P O, Perlman E, Flam F, Frieman M B, Feinberg A P. A genome-wide screen for normally methylated human CpG islands that can identify novel imprinted genes. Genome Res. 2002; 12: 543–54. [PUBMED], [INFOTRIEVE]
- Suzumori K, Yamauchi M, Seki N, Kondo I, Hori T. Prenatal diagnosis of a hypermethylated full fragile X mutation in chorionic villi of a male fetus. J Med Genet. 1993; 30: 785–7. [PUBMED], [INFOTRIEVE]
- Allegrucci C, Denning C, Priddle H, Young L. Stem-cell consequences of embryo epigenetic defects. Lancet. 2004; 364: 206–8. [PUBMED], [INFOTRIEVE]
- De, Smet C, Loriot A, Boon T. Promoter-dependent mechanism leading to selective hypomethylation within the 5′ region of gene MAGE-A1 in tumor cells. Mol Cell Biol. 2004; 24: 4781–90. [PUBMED], [INFOTRIEVE]
- Cisneros F J. DNA methylation and male infertility. Front Biosci. 2004; 9: 1189–1200. [PUBMED], [INFOTRIEVE]
- Benchaib M, Ajina M, Lornage J, Niveleau A, Durand P, Guerin J F. Quantitation by image analysis of global DNA methylation in human spermatozoa and its prognostic value in in vitro fertilization: A preliminary study. Fertil Steril. 2003; 80: 947–53. [PUBMED], [INFOTRIEVE]
- Haines T R, Rodenhiser D I, Ainsworth P J. Allele-specific non-CpG methylation of the Nf1 gene during early mouse development. Dev Biol. 2001; 240: 585–98. [PUBMED], [INFOTRIEVE]
- Widschwendter M, Jiang G, Woods C, Muller H M, Fiegl H, Goebel G, Marth C, Muller-Holzner E, Zeimet A G, Laird P W, Ehrlich M. DNA hypomethylation and ovarian cancer biology. Cancer Res. 2004; 64: 4472–80. [PUBMED], [INFOTRIEVE]
- Widschwendter A, Muller H M, Hubalek M M, Wiedemair A, Fiegl H, Goebel G, Mueller-Holzner E, Marth C, Widschwendter M. Methylation status and expression of human telomerase reverse transcriptase in ovarian and cervical cancer. Gynecol Oncol. 2004; 93: 407–16. [PUBMED], [INFOTRIEVE]
- Burrows J F, Chanduloy S, McIlhatton M A, Nagar H, Yeates K, Donaghy P, Price J, Godwin A K, Johnston P G, Russell S E. Altered expression of the septin gene, SEPT9, in ovarian neoplasia. J Pathol. 2003; 201: 581–8. [PUBMED], [INFOTRIEVE]
- Chen H Z, Ye D F, Xie X, Hu M, Lu W G. Hypermethylation of hMLH1 and microsatellite instability in ovarian mucinous tumors. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2003; 25: 457–61. [PUBMED], [INFOTRIEVE]
- Futscher B W, O'Meara M M, Kim C J, Rennels M A, Lu D, Gruman L M, Seftor R E, Hendrix M J, Domann F E. Aberrant methylation of the maspin promoter is an early event in human breast cancer. Neoplasia. 2004; 6: 380–9. [PUBMED], [INFOTRIEVE]
- Bandyopadhyay S, Pai S K, Hirota S, Hosobe S, Takano Y, Saito K, Piquemal D, Commes T, Watabe M, Gross S C, Wang Y, Ran S, Watabe K. Role of the putative tumor metastasis suppressor gene Drg-1 in breast cancer progression. Oncogene. 2004; 23: 5675–1. [PUBMED], [INFOTRIEVE]
- Widschwendter M, Siegmund K D, Muller H M, Fiegl H, Marth C, Muller-Holzner E, Jones P A, Laird P W. Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res. 2004; 64: 3807–13. [PUBMED], [INFOTRIEVE]
- David G L, Yegnasubramanian S, Kumar A, Marchi V L, de, Marzo A M, Lin X, Nelson W G. MDR1 Promoter hypermethylation in MCF-7 human breast cancer cell: Changes in chromatin structure induced by treatment with 5-Aza-Cytidine. Cancer Biol Ther. 2004; 3: 540–8. [PUBMED], [INFOTRIEVE]
- Sathyanarayana U G, Padar A, Huang C X, Suzuki M, Shigematsu H, Bekele B N, Gazdar A F. Aberrant promoter methylation and silencing of laminin-5-encoding genes in breast carcinoma. Clin Cancer Res. 2003; 9: 6389–94. [PUBMED], [INFOTRIEVE]
- Stuppia L, Guanciali Franchi P, Parruti G, Calabrese G, Bianchi U, Palka G. In situ Hpa II endonuclease digestion on fixed chromatin of solid tumor cells. Tumori. 1990; 76: 530–2. [PUBMED], [INFOTRIEVE]
- Esteller M, Catasus L, Matias-Guiu X, Mutter G L, Prat J, Baylin S B, Herman J G. hMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis. Am J Pathol. 1999; 155: 1767–72. [PUBMED], [INFOTRIEVE]
- Esteller M, Hamilton S R, Burger P C, Baylin S B, Herman J G. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 1999; 59: 793–7. [PUBMED], [INFOTRIEVE]
- Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin S B, Herman J G. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res. 1999; 59: 67–70. [PUBMED], [INFOTRIEVE]
- Jones P A, Laird P W. Cancer epigenetics comes of age. Nat Genet. 1999; 21: 163–7. [PUBMED], [INFOTRIEVE]
- Tycko B. Epigenetic gene silencing in cancer. J Clin Invest. 2000; 105: 401–7. [PUBMED], [INFOTRIEVE]
- Akhtar M, Cheng Y, Magno R M, Ashktorab H, Smoot D T, Meltzer S J, Wilson K T. Promoter methylation regulates Helicobacter pylori-stimulated cyclooxygenase-2 expression in gastric epithelial cells. Cancer Res. 2001; 61: 2399–2403. [PUBMED], [INFOTRIEVE]
- Ahluwalia A, Yan P, Hurteau J A, Bigsby R M, Jung S H, Huang T H, Nephew K P. DNA methylation and ovarian cancer. I. Analysis of CpG island hypermethylation in human ovarian cancer using differential methylation hybridization. Gynecol Oncol. 2001; 82: 261–8. [PUBMED], [INFOTRIEVE]
- Ahluwalia A, Hurteau J A, Bigsby R M, Nephew K P. DNA methylation in ovarian cancer. II. Expression of DNA methyltransferases in ovarian cancer cell lines and normal ovarian epithelial cells. Gynecol Oncol. 2001; 82: 299–304. [PUBMED], [INFOTRIEVE]
- Baylin S B, Herman J G. DNA hypermethylation in tumorigenesis: Epigenetics joins genetics. Trends Genet. 2000; 16: 168–74. [PUBMED], [INFOTRIEVE]
- Ng H H, Zhang Y, Hendrich B, Johnson C A, Turner B M, Erdjument-Bromage H, Tempst P, Reinberg D, Bird A. MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex. Nat Genet. 1999; 23: 58–61. [PUBMED], [INFOTRIEVE]
- Wade P A, Gegonne A, Jones P L, Ballestar E, Aubry F, Wolffe A P. Mi-2 complex couples DNA methylation to chromatin remodelling and histone deacetylation. Nat Genet. 1999; 23: 62–6. [PUBMED], [INFOTRIEVE]
- Nan B C, Shao D M, Chen H L, Huang Y, Gu J X, Zhang Y B, Wu Z G. Alteration of N-acetylglucosaminyltransferases in pancreatic carcinoma. Glycoconj J. 1998; 15: 1033–7. [PUBMED], [INFOTRIEVE]
- Barbieri R, Mischiati C, Piva R, Nastruzzi C, Giacomini P, Natali P G, Gambari R. DNA methylation of the Ha-ras-1 oncogene in neoplastic cells. Anticancer Res. 1989; 9: 1787–91. [PUBMED], [INFOTRIEVE]
- Hanada M, Delia D, Aiello A, Stadtmauer E, Reed J C. bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood. 1993; 82: 1820–8. [PUBMED], [INFOTRIEVE]
- Ray J S, Harbison M L, McClain R M, Goodman J I. Alterations in the methylation status and expression of the raf oncogene in phenobarbital-induced and spontaneous B6C3F1 mouse live tumors. Mol Carcinog. 1994; 9: 155–66. [PUBMED], [INFOTRIEVE]
- Rao P M, Antony A, Rajalakshmi S, Sarma D S. Studies on hypomethylation of liver DNA during early stages of chemical carcinogenesis in rat liver. Carcinogenesis. 1989; 10: 933–7. [PUBMED], [INFOTRIEVE]
- Vachtenheim J, Horakova I, Novotna H. Hypomethylation of CCGG sites in the 3′ region of H-ras protooncogene is frequent and is associated with H-ras allele loss in non-small cell lung cancer. Cancer Res. 1994; 54: 1145–8. [PUBMED], [INFOTRIEVE]
- Feinberg A P, Vogelstein B. Hypomethylation of ras oncogenes in primary human cancers. Biochem Biophys Res Commun. 1983; 111: 47–54. [PUBMED], [INFOTRIEVE]
- Feinberg A P, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature. 1983; 301: 89–92. [PUBMED], [INFOTRIEVE]
- Chandler L A, DeClerck Y A, Bogenmann E, Jones P A. Patterns of DNA methylation and gene expression in human tumor cell lines. Cancer Res. 1986; 46: 2944–9. [PUBMED], [INFOTRIEVE]
- Issaq H J, Veenstra T D, Conrads T P, Felschow D. The SELDI-TOF MS approach to proteomics: Protein profiling and biomarker identification. Biochem Biophys Res Commun. 2002; 292: 587–92. [PUBMED], [INFOTRIEVE]
- Issa J P. The epigenetics of colorectal cancer. Ann NY Acad Sci. 2000; 910: 140–53. [PUBMED], [INFOTRIEVE]
- Kondo Y, Issa J P. Epigenetic changes in colorectal cancer. Cancer Metastasis Rev. 2004; 23: 29–39. [PUBMED], [INFOTRIEVE]
- Youssef E M, Estecio M R, Issa J P.. Methylation and regulation of expression of different retinoic acid receptor beta isoforms in human colon cancer. Cancer Biol Ther. 2004; 3: 82–6. [PUBMED], [INFOTRIEVE]
- Issa J P, Ahuja N, Toyota M, Bronner M P, Brentnall T A. Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res. 2001; 61: 3573–7. [PUBMED], [INFOTRIEVE]
- Yeager T R, DeVries S, Jarrard D F, Kao C, Nakada S Y, Moon T D, Bruskewitz R, Stadler W M, Meisner L F, Gilchrist K W, Newton M A, Waldman F M, Reznikoff C A. Overcoming cellular senescence in human cancer pathogenesis. Genes Dev. 1998; 12: 163–74. [PUBMED], [INFOTRIEVE]
- Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan R S, Zborowska E, Kinzler K W, Vogelstein B. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science. 1995; 268: 1336–8. [PUBMED], [INFOTRIEVE]
- Boland C R, Thibodeau S N, Hamilton S R, Sidransky D, Eshleman J R, Burt R W, Meltzer S J, Rodriguez-Bigas M A, Fodde R, Ranzani G N, Srivastava S. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: Development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998; 58: 5248–57. [PUBMED], [INFOTRIEVE]
- Zheng M, Wang H, Zhang H, Ou Q, Shen B, Li N, Yu B. The influence of the p53 gene on the in vitro chemosensitivity of colorectal cancer cells. J Cancer Res Clin Oncol. 1999; 125: 357–60. [PUBMED], [INFOTRIEVE]
- Shanahan F. Review article: Colitis-associated cancer—time for new strategies. Aliment Pharmacol Ther. 2003; 18: 6–9. [PUBMED], [INFOTRIEVE]
- Munkholm P. Review article: The incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther. 2003; 18: 1–5. [PUBMED], [INFOTRIEVE]
- Croog V J, Ullman T A, Itzkowitz S H. Chemoprevention of colorectal cancer in ulcerative colitis. Int J Colorectal Dis. 2003; 18: 392–400. [PUBMED], [INFOTRIEVE]
- Vera A, Gunson B K, Ussatoff V, Nightingale P, Candinas D, Radley S, Mayer A D, Buckels J A, McMaster P, Neuberger J, Mirza D F. Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Transplantation. 2003; 75: 1983–8. [PUBMED], [INFOTRIEVE]
- Kiesslich R, Fritsch J, Holtmann M, Koehler H H, Stolte M, Kanzler S, Nafe B, Jung M, Galle P R, Neurath M F. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology. 2003; 124: 880–8. [PUBMED], [INFOTRIEVE]
- Sato F, Harpaz N, Shibata D, Xu Y, Yin J, Mori Y, Zou T T, Wang S, Desai K, Leytin A, Selaru F M, Abraham J M, Meltzer S J. Hypermethylation of the p14(ARF) gene in ulcerative colitis-associated colorectal carcinogenesis. Cancer Res. 2002; 62: 1148–51. [PUBMED], [INFOTRIEVE]
- Jeronimo C, Varzim G, Henrique R, Oliveira J, Bento M J, Silva C, Lopes C, Sidransky D. I105V polymorphism and promoter methylation of the GSTP1 gene in prostate adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2002; 11: 445–50. [PUBMED], [INFOTRIEVE]
- Jeronimo C, Usadel H, Henrique R, Oliveira J, Lopes C, Nelson W G, Sidransky D. Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J Natl Cancer Inst. 2001; 93: 1747–52. [PUBMED], [INFOTRIEVE]
- Kambara T, Simms L A, Whitehall V L, Spring K J, Wynter C V, Walsh M D, Barker M A, Arnold S, McGivern A, Matsubara N, Tanaka N, Higuchi T, Young J, Jass J R, Leggett B A. BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut. 2004; 53: 1137–44. [PUBMED], [INFOTRIEVE]
- Yegnasubramanian S, Kowalski J, Gonzalgo M L, Zahurak M, Piantadosi S, Walsh P C, Bova G S, de, Marzo A M, Isaacs W B, Nelson W G. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res. 2004; 64: 1975–86. [PUBMED], [INFOTRIEVE]
- Gonzalgo M L, Nakayama M, Lee S M, de, Marzo A M, Nelson W G. Detection of GSTP1 methylation in prostatic secretions using combinatorial MSP analysis. Urology. 2004; 63: 414–8. [PUBMED], [INFOTRIEVE]
- Nakayama M, Gonzalgo M L, Yegnasubramanian S, Lin X, de, Marzo A M, Nelson W G. GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer. J Cell Biochem. 2004; 91: 540–52. [PUBMED], [INFOTRIEVE]
- De, Marzo A M, Meeke A K, Zha S, Luo J, Nakayama M, Platz E A, Isaacs W B, Nelson W G. Human prostate cancer precursors and pathobiology. Urology. 2003; 62: 55–62
- Enzinger P C. Should people with Barrett's esophagus, who are at risk for cancer of the esophagus, avoid alcohol?. Health News. 2004; 10: 16, [PUBMED], [INFOTRIEVE]
- Katz P O. Management of the patient with Barrett's esophagus: A continuing dilemma for the clinician. Rev Gastroenterol Disord. 2004; 4: 49–59. [PUBMED], [INFOTRIEVE]
- Shalauta M D, Saad R. Barrett's esophagus. Am Fam Physician. 2004; 69: 2113–8. [PUBMED], [INFOTRIEVE]
- DeVault K R. Screening for Barrett's esophagus. Am Fam Physician. 2004; 69: 2061–3. [PUBMED], [INFOTRIEVE]
- Metzger R, Schneider P M, Warnecke-Eberz U, Brabender J, Holscher A H. Molecular biology of esophageal cancer. Onkologie. 2004; 27: 200–6. [PUBMED], [INFOTRIEVE]
- Bian Y S, Osterheld M C, Fontolliet C, Bosman F T, Benhattar J. p16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett's esophagus. Gastroenterology. 2002; 122: 1113–21. [PUBMED], [INFOTRIEVE]
- Xing E P, Nie Y, Song Y, Yang G Y, Cai Y C, Wang L D, Yang C S. Mechanisms of inactivation of p14ARF, p15INK4b, and p16INK4a genes in human esophageal squamous cell carcinoma. Clin Cancer Res. 1999; 5: 2704–13. [PUBMED], [INFOTRIEVE]
- Xing E P, Nie Y, Wang L D, Yang G Y, Yang C S. Aberrant methylation of p16INK4a and deletion of p15INK4b are frequent events in human esophageal cancer in Linxian, China. Carcinogenesis. 1999; 20: 77–84. [PUBMED], [INFOTRIEVE]
- Klump B, Hsieh C J, Holzmann K, Gregor M, Porschen R. Hypermethylation of the CDKN2/p16 promoter during neoplastic progression in Barrett's esophagus. Gastroenterology. 1998; 115: 1381–6. [PUBMED], [INFOTRIEVE]
- Laird P W. The power and the promise of DNA methylation markers. Nat Rev Cancer. 2003; 3: 253–66. [PUBMED], [INFOTRIEVE]
- Laird C D, Pleasant N D, Clark A D, Sneeden J L, Hassan K M, Manley N C, Vary J C, Morgan T, Hansen R S, Stoger R. Hairpin-bisulfite PCR: Assessing epigenetic methylation patterns on complementary strands of individual DNA molecules. Proc Natl Acad Sci USA. 2004; 101: 204–9. [PUBMED], [INFOTRIEVE]
- Toyota M, Shen L, Ohe-Toyota M, Hamilton S R, Sinicrope F A, Issa J P. Aberrant methylation of the Cyclooxygenase 2 CpG island in colorectal tumors. Cancer Res. 2000; 60: 4044–8. [PUBMED], [INFOTRIEVE]
- Juttermann R, Li E, Jaenisch R. Toxicity of 5-aza-2′-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci USA. 1994; 91: 11797–801. [PUBMED], [INFOTRIEVE]
- Bouchard J, Momparler R L. Incorporation of 5-Aza-2′-deoxycytidine-5′-triphosphate into DNA. Interactions with mammalian DNA polymerase alpha and DNA methylase. Mol Pharmacol. 1983; 24: 109–4. [PUBMED], [INFOTRIEVE]
- Santi D V, Garrett C E, Barr P J. On the mechanism of inhibition of DNA-cytosine methyltransferases by cytosine analogs. Cell. 1983; 33: 9–10. [PUBMED], [INFOTRIEVE]
- Goffin J, Eisenhauer E. DNA methyltransferase inhibitors-state of the art. Ann Oncol. 2002; 13: 1699–716. [PUBMED], [INFOTRIEVE]
- Cheng J C, Matsen C B, Gonzales F A, Ye W, Greer S, Marquez V E, Jones P A, Selker E U. Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst. 2003; 95: 399–409. [PUBMED], [INFOTRIEVE]
- Lin X, Asgari K, Putzi M J, Gage W R, Yu X, Cornblatt B S, Kumar A, Piantadosi S, DeWeese T L, de, Marzo A M, Nelson W G. Reversal of GSTP1 CpG island hypermethylation and reactivation of pi-class glutathione S-transferase (GSTP1) expression in human prostate cancer cells by treatment with procainamide. Cancer Res. 2001; 61: 8611–6. [PUBMED], [INFOTRIEVE]
- Dunn B K, Verma M, Umar A. Epigenetics in cancer prevention: Early detection and risk assessment: Introduction. Ann NY Acad Sci. 2003; 983: 1–4. [PUBMED], [INFOTRIEVE]
- Marks P A, Richon V M, Breslow R, Rifkind R A. Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol. 2001; 13: 477–83. [PUBMED], [INFOTRIEVE]
- Kopelovich L, Crowell J A, Fay J R. The epigenome as a target for cancer chemoprevention. J Natl Cancer Inst. 2003; 95: 1747–57. [PUBMED], [INFOTRIEVE]
- Grignani F, de, Matteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M, Fanelli M, Ruthardt M, Ferrara F F, Zamir I, Seiser C, Lazar M A, Minucci S, Pelicci P G. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature. 1998; 391: 815–8. [PUBMED], [INFOTRIEVE]
- Lin R J, Nagy L, Inoue S, Shao W, Miller W H, Evans R M. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature. 1998; 391: 811–4. [PUBMED], [INFOTRIEVE]
- Warrell R P, He L Z, Richon V, Calleja E, Pandolfi P P. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst. 1998; 90: 1621–5. [PUBMED], [INFOTRIEVE]
- Gore S D, Weng L J, Figg W D, Zhai S, Donehower R C, Dover G, Grever M R, Griffin C, Grochow L B, Hawkins A, Burks K, Zabelena Y, Miller C B. Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin Cancer Res. 2002; 8: 963–70. [PUBMED], [INFOTRIEVE]
- Newmark H L, Young C W.. Butyrate and phenylacetate as differentiating agents: Practical problems and opportunities. J Cell Biochem Suppl. 1995; 22: 247–53. [PUBMED], [INFOTRIEVE]
- Gottlicher M, Minucci S, Zhu P, Kramer O H, Schimpf A, Giavara S, Sleeman J P, Lo, Coco F, Nervi C, Pelicci P G, Heinzel T. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 2001; 20: 6969–78. [PUBMED], [INFOTRIEVE]
- Van, Lint C, Emiliani S, Verdin E. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr. 1996; 5: 245–53. [PUBMED], [INFOTRIEVE]
- Momparler R L, Cote S, Eliopoulos N. Pharmacological approach for optimization of the dose schedule of 5-Aza-2′-deoxycytidine (Decitabine) for the therapy of leukemia. Leukemia. 1997; 1: S1–6
- Mintz A, Debinski W. Cancer genetics/epigenetics and the X chromosome: Possible new links for malignant glioma pathogenesis and immune-based therapies. Crit Rev Oncog. 2000; 11: 77–95. [PUBMED], [INFOTRIEVE]
- Lee S, Hwang K S, Lee H J, Kim J S, Kang G H. Aberrant CpG island hypermethylation of multiple genes in colorectal neoplasia. Lab Invest. 2004; 84: 884–93. [PUBMED], [INFOTRIEVE]
- O'Brien M J, Yang S, Clebanoff J L, Mulcahy E, Farraye F A, Amorosino M, Swan N. Hyperplastic (serrated) polyps of the colorectum: Relationship of CpG island methylator phenotype and K-ras mutation to location and histologic subtype. Am J Surg Pathol. 2004; 28: 423–34. [PUBMED], [INFOTRIEVE]
- Sabbioni S, Miotto E, Veronese A, Sattin E, Gramantieri L, Bolondi L, Calin G A, Gafa R, Lanza G, Carli G, Ferrazzi E, Feo C, Liboni A, Gullini S, Negrini M. Multigene methylation analysis of gastrointestinal tumors: TPEF emerges as a frequent tumor-specific aberrantly methylated marker that can be detected in peripheral blood. Mol Diagn. 2003; 7: 201–7. [PUBMED], [INFOTRIEVE]
- Wynter C V, Walsh M D, Higuchi T, Leggett B A, Young J, Jass J R. Methylation patterns define two types of hyperplastic polyp associated with colorectal cancer. Gut. 2004; 53: 573–80. [PUBMED], [INFOTRIEVE]
- Rodriguez-Dorantes M, Tellez-Ascencio N, Cerbon M A, Lopez M, Cervantes A. DNA methylation: An epigenetic process of medical importance. Rev Invest Clin. 2004; 56: 56–71. [PUBMED], [INFOTRIEVE]
- Verma M, Srivastava S. New cancer biomarkers deriving from NCI early detection research. Recent Results Cancer Res. 2003; 163: 72–84. [PUBMED], [INFOTRIEVE]
- Cho B, Lee H, Jeong S, Bang Y J, Lee H J, Hwang K S, Kim H Y, Lee Y S, Kang G H, Jeoung D I. Promoter hypomethylation of a novel cancer/testis antigen gene CAGE is correlated with its aberrant expression and is seen in premalignant stage of gastric carcinoma. Biochem Biophys Res Commun. 2003; 307: 52–63. [PUBMED], [INFOTRIEVE]
- Oshimo Y, Nakayama H, Ito R, Kitadai Y, Yoshida K, Chayama K, Yasui W. Promoter methylation of cyclin D2 gene in gastric carcinoma. Int J Oncol. 2003; 23: 1663–70. [PUBMED], [INFOTRIEVE]
- Akiyama Y, Maesawa C, Ogasawara S, Terashima M, Masuda T. Cell-type-specific repression of the maspin gene is disrupted frequently by demethylation at the promoter region in gastric intestinal metaplasia and cancer cells. Am J Pathol. 2003; 163: 1911–9. [PUBMED], [INFOTRIEVE]
- Ogasawara S, Maesawa C, Yamamoto M, Akiyama Y, Wada K, Fujisawa K, Higuchi T, Tomisawa Y, Sato N, Endo S, Saito K, Masuda T. Disruption of cell-type-specific methylation at the Maspin gene promoter is frequently involved in undifferentiated thyroid cancers. Oncogene. 2004; 23: 1117–24. [PUBMED], [INFOTRIEVE]
- Nakamura N, Takenaga K. Hypomethylation of the metastasis-associated S100A4 gene correlates with gene activation in human colon adenocarcinoma cell lines. Clin Exp Metastasis. 1998; 16: 471–9. [PUBMED], [INFOTRIEVE]
- Shaker S, Bernstein M, Momparler L F, Momparler R L. Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-2′-deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells. Leuk Res. 2003; 27: 437–44. [PUBMED], [INFOTRIEVE]
- Cameron E E, Bachman K E, Myohanen S, Herman J G, Baylin S B. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet. 1999; 21: 103–7. [PUBMED], [INFOTRIEVE]
- Chaumeil J, Okamoto I, Guggiari M, Heard E. Integrated kinetics of X chromosome inactivation in differentiating embryonic stem cells. Cytogenet Genome Res. 2002; 99: 75–84. [PUBMED], [INFOTRIEVE]
- Kim K C, Huang S. Histone methyltransferases in tumor suppression. Cancer Biol Ther. 2003; 2: 491–9. [PUBMED], [INFOTRIEVE]
- Hadorn E, Gsell R, Schultz J. Stability of a position-effect variegation in normal and transdetermined larval blastemas from Drosophila melanogaster. Proc Natl Acad Sci USA. 1970; 65: 633–7. [PUBMED], [INFOTRIEVE]
- Konduri S D, Srivenugopal K S, Yanamandra N, Dinh D H, Olivero W C, Gujrati M, Foster D C, Kisiel W, Ali-Osman F, Kondraganti S, Lakka S S, Rao J S. Promoter methylation and silencing of the tissue factor pathway inhibitor-2 (TFPI-2), a gene encoding an inhibitor of matrix metalloproteinases in human glioma cells. Oncogene. 2003; 22: 4509–16. [PUBMED], [INFOTRIEVE]
- Fahrner J A, Eguchi S, Herman J G, Baylin S B. Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res. 2002; 62: 7213–18. [PUBMED], [INFOTRIEVE]
- Mushegian A R, Garey J R, Martin J, Liu L X. Large-scale taxonomic profiling of eukaryotic model organisms: A comparison of orthologous proteins encoded by the human, fly, nematode, and yeast genomes. Genome Res. 1998; 8: 590–8. [PUBMED], [INFOTRIEVE]
- Ziemin-van derPoel S, McCabe N R, Gill H J, Espinosa R, Patel Y, Harden A, Rubinelli P, Smith S D, LeBeau M M, Rowley J D. Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias. Proc Natl Acad Sci USA. 1991; 88: 10735–9
- Gu Y, Nakamura T, Alder H, Prasad R, Canaani O, Cimino G, Croce C M, Canaani E. The t(4;11) chromosome translocation of human acute leukemias fuses the ALL-1 gene, related to Drosophila trithorax, to the AF-4 gene. Cell. 1992; 71: 701–8. [PUBMED], [INFOTRIEVE]
- Djabali M, Selleri L, Parry P, Bower M, Young B, Evans G A. A trithorax-like gene is interrupted by chromosome 11q23 translocations in acute leukaemias. Nat Genet. 1993; 4: 431, [PUBMED], [INFOTRIEVE]
- Peters A H, O'Carroll D, Scherthan H, Mechtler K, Sauer S, Schofer C, Weipoltshammer K, Pagani M, Lachner M, Kohlmaier A, Opravil S, Doyle M, Sibilia M, Jenuwein T. Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability. Cell. 2001; 107: 323–7. [PUBMED], [INFOTRIEVE]
- Laird P W, Jackson-Grusby L, Fazeli A, Dickinson S L, Jung W E, Li E, Weinberg R A, Jaenisch R. Suppression of intestinal neoplasia by DNA hypomethylation. Cell. 1995; 81: 197–205. [PUBMED], [INFOTRIEVE]
- Chen W Y, Zeng X, Carter M G, Morrell C N, Chiu Yen RW, Esteller M, Watkins D N, Herman J G, Mankowski J L, Baylin S B. Heterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrum of malignant tumors. Nat Genet. 2003; 33: 197–202. [PUBMED], [INFOTRIEVE]
- Gaudet F, Hodgson J G, Eden A, Jackson-Grusby L, Dausman J, Gray J W, Leonhardt H, Jaenisch R. Induction of tumors in mice by genomic hypomethylation. Science. 2003; 300: 489–92. [PUBMED], [INFOTRIEVE]
- Butler L M, Agus D B, Scher H I, Higgins B, Rose A, Cordon-Cardo C, Thaler H T, Rifkind R A, Marks P A, Richon V M. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. 2000; 60: 5165–70. [PUBMED], [INFOTRIEVE]
- Grem J L, Shoemaker D D, Hoth D F, King S A, Plowman J, Zaharko D, Grieshaber C K, Harrison S D, Cradock J C, Leyland-Jones B. Arabinosyl-5-azacytosine: A novel nucleoside entering clinical trials. Invest New Drugs. 1987; 5: 315–28. [PUBMED], [INFOTRIEVE]
- Vesely J, Piskala A. Mechanism of action of 1-beta-D-arabinofuranosyl-5-azacytosine and its effects in L1210 mouse leukemia cells. Neoplasma. 1986; 33: 3–10. [PUBMED], [INFOTRIEVE]
- Liang G, Chan M F, Tomigahara Y, Tsai Y C, Gonzales F A, Li E, Laird P W, Jones P A. Cooperativity between DNA methyltransferases in the maintenance methylation of repetitive elements. Mol Cell Biol. 2002; 22: 480–91. [PUBMED], [INFOTRIEVE]
- Lindsey J C, Lusher M E, Anderton J A, Bailey S, Gilbertson R J, Pearson A D, Ellison D W, Clifford S C. Identification of tumour-specific epigenetic events in medulloblastoma development by hypermethylation profiling. Carcinogenesis. 2004; 25: 661–8. [PUBMED], [INFOTRIEVE]
- Alonso M E, Bello M J, Gonzalez-Gomez P, Arjona D, Lomas J, de, Campos J M, Isla A, Sarasa J L, Rey J A. Aberrant promoter methylation of multiple genes in oligodendrogliomas and ependymomas. Cancer Genet Cytogenet. 2003; 144: 134–42. [PUBMED], [INFOTRIEVE]
- Rousseau E, Ruchoux M M, Scaravilli F, Chapon F, Vinchon M, de, Smet C, Godfraind C, Vikkula M. CDKN2A, CDKN2B and p14ARF are frequently and differentially methylated in ependymal tumours. Neuropathol Appl Neurobiol. 2003; 29: 574–83. [PUBMED], [INFOTRIEVE]
- Chan M W, Chan L W, Tang N L, Tong J H, Lo K W, Lee T L, Cheung H Y, Wong W S, Chan P S, Lai F M, To K F. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res. 2002; 8: 464–70. [PUBMED], [INFOTRIEVE]
- Maruyama R, Toyooka S, Toyooka K O, Harada K, Virmani A K, Zochbauer-Muller S, Farinas A J, Vakar-Lopez F, Minna J D, Sagalowsky A, Czerniak B, Gazdar A F. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res. 2001; 61: 8659–63. [PUBMED], [INFOTRIEVE]
- Gutierrez M I, Siraj A K, Khaled H, Koon N, El-Rifai W, Bhatia K. CpG island methylation in Schistosoma- and non-Schistosoma-associated bladder cancer. Mol Pathol. 2004; 17: 1268–74
- Gonzalez-Gomez P, Bello M J, Alonso M E, Aminoso C, Lopez-Marin I, de, Campos J M, Isla A, Gutierrez M, Rey J A. Promoter methylation status of multiple genes in brain metastases of solid tumors. Int J Mol Med. 2004; 13: 93–8. [PUBMED], [INFOTRIEVE]
- Dolan M E, Posner M, Karrison T, Radosta J, Steinberg G, Bertucci D, Vujasin L, Ratain M J. Determination of the optimal modulatory dose of O6-benzylguanine in patients with surgically resectable tumors. Clin Cancer Res. 2002; 8: 2519–23. [PUBMED], [INFOTRIEVE]
- Miyakura Y, Sugano K, Akasu T, Yoshida T, Maekawa M, Saitoh S, Sasaki H, Nomizu T, Konishi F, Fujita S, Moriya Y, Nagai H. Extensive but hemiallelic methylation of the hMLH1 promoter region in early-onset sporadic colon cancers with microsatellite instability. Clin Gastroenterol Hepatol. 2004; 2: 147–56. [PUBMED], [INFOTRIEVE]
- Kondo E, Furukawa T, Yoshinaga K, Kijima H, Semba S, Yatsuoka T, Yokoyama T, Fukushige S, Horii A. Not hMSH2 but hMLH1 is frequently silenced by hypermethylation in endometrial cancer but rarely silenced in pancreatic cancer with microsatellite instability. Int J Oncol. 2000; 17: 535–41. [PUBMED], [INFOTRIEVE]
- Pellise M, Castells A, Gines A, Agrelo R, Sole M, Castellvi-Bel S, Fernandez-Esparrach G, Llach J, Esteller M, Bordas J M, Pique J M. Detection of lymph node micrometastases by gene promoter hypermethylation in samples obtained by endosonography- guided fine-needle aspiration biopsy. Clin Cancer Res. 2004; 10: 4444–9. [PUBMED], [INFOTRIEVE]
- Kwong F M, Tang J C, Srivastava G, Lung M L. Inactivation mechanisms and growth suppressive effects of p16INK4a in Asian esophageal squamous carcinoma cell lines. Cancer Lett. 2004; 208: 207–13. [PUBMED], [INFOTRIEVE]
- Brock M V, Gou M, Akiyama Y, Muller A, Wu T T, Montgomery E, Deasel M, Germonpre P, Rubinson L, Heitmiller R F, Yang S C, Forastiere A A, Baylin S B, Herman J G. Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin Cancer Res. 2003; 9: 2912–9. [PUBMED], [INFOTRIEVE]
- Hibi K, Nakayama H, Kanyama Y, Kodera Y, Ito K, Akiyama S, Nakao A. Methylation pattern of HLTF gene in digestive tract cancers. Int J Cancer. 2003; 104: 433–6. [PUBMED], [INFOTRIEVE]
- Nie Y, Liao J, Zhao X, Song Y, Yang G Y, Wang L D, Yang C S. Detection of multiple gene hypermethylation in the development of esophageal squamous cell carcinoma. Carcinogenesis. 2002; 23: 1713–20. [PUBMED], [INFOTRIEVE]
- Maruya S, Issa J P, Weber R S, Rosenthal D I, Haviland J C, Lotan R, El-Naggar A K. Differential methylation status of tumor-associated genes in head and neck squamous carcinoma: Incidence and potential implications. Clin Cancer Res. 2004; 10: 3825–30. [PUBMED], [INFOTRIEVE]
- Goldenberg D, Harden S, Masayesva B G, Ha P, Benoit N, Westra W H, Koch W M, Sidransky D, Califano J A. Intraoperative molecular margin analysis in head and neck cancer. Arch Otolaryngol Head Neck Surg. 2004; 130: 39–44. [PUBMED], [INFOTRIEVE]
- Tripathi Bhar A, Banerjee S, Chunder N, Roy A, Sengupta A, Roy B, Roychowdhury S, Panda C K. Differential alterations of the genes in the CDKN2A-CCND1-CDK4-RB1 pathway are associated with the development of head and neck squamous cell carcinoma in Indian patients. J Cancer Res Clin Oncol. 2003; 129: 642–50
- Dulaimi E, De C, Uzzo R G, Al-Saleem T, Greenberg R E, Polascik T J, Babb J S, Grizzle W E, Cairns P. Promoter hypermethylation profile of kidney cancer. Clin Cancer Res. 2004; 10: 3972–9. [PUBMED], [INFOTRIEVE]
- Morris M R, Hesson L B, Wagner K J, Morgan N V, Astuti D, Lees R D, Cooper W N, Lee J, Gentle D, Macdonald F, Kishida T, Grundy R, Yao M, Latif F, Maher E R. Multigene methylation analysis of Wilms' tumour and adult renal cell carcinoma. Oncogene. 2003; 22: 6794–6801. [PUBMED], [INFOTRIEVE]
- Chung W B, Hong S H, Kim J A, Sohn Y K, Kim B W, Kim J W. Hypermethylation of tumor-related genes in genitourinary cancer cell lines. J Korean Med Sci. 2001; 16: 756–61. [PUBMED], [INFOTRIEVE]
- Esteller M. Profiling aberrant DNA methylation in hematologic neoplasms: A view from the tip of the iceberg. Clin Immunol. 2003; 109: 80–8. [PUBMED], [INFOTRIEVE]
- Chim C S, Kwong Y L, Fung T K, Liang R. Methylation profiling in multiple myeloma. Leuk Res. 2004; 28: 379–85. [PUBMED], [INFOTRIEVE]
- Kim J S, Kim H, Shim Y M, Han J, Park J, Kim D H. Aberrant methylation of the FHIT gene in chronic smokers with early stage squamous cell carcinoma of the lung. Carcinogenesis. 2004, (in press).
- Kim H, Kwon Y M, Kim J S, Lee H, Park J H, Shim Y M, Han J, Park J, Kim D H. Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer. J Clin Oncol. 2004; 22: 2363–70. [PUBMED], [INFOTRIEVE]
- Maruyama R, Sugio K, Yoshino I, Maehara Y, Gazdar A F. Hypermethylation of FHIT as a prognostic marker in nonsmall cell lung carcinoma. Cancer. 2004; 100: 1472–77. [PUBMED], [INFOTRIEVE]
- Han S Y, Iliopoulos D, Druck T, Guler G, Grubbs C J, Pereira M, Zhang Z, You M, Lubet R A, Fong L Y, Huebner K. CpG methylation in the Fhit regulatory region: Relation to Fhit expression in murine tumors. Oncogene. 2004; 23: 3990–8. [PUBMED], [INFOTRIEVE]
- Wang C, Horiuchi A, Imai T, Ohira S, Itoh K, Nikaido T, Katsuyama Y, Konishi I. Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene. J Pathol. 2004; 202: 215–3. [PUBMED], [INFOTRIEVE]
- Marsit C J, Liu M, Nelson H H, Posner M, Suzuki M, Kelsey K T. Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: Implications for treatment and survival. Oncogene. 2004; 23: 1000–4. [PUBMED], [INFOTRIEVE]
- Geisler J P, Rathe J A, Manahan K J, Geisler H E. Methylation: A second hit in the two-hit hypothesis. Eur J Gynaecol Oncol. 2003; 24: 361, [PUBMED], [INFOTRIEVE]
- Jhanwar-Uniyal M. BRCA1 in cancer, cell cycle and genomic stability. Front Biosci. 2003; 8: s1107–17. [PUBMED], [INFOTRIEVE]
- Olopade O I. Wei M FANCF methylation contributes to chemoselectivity in ovarian cancer. Cancer Cell. 2003; 3: 417–420. [PUBMED], [INFOTRIEVE]
- House M G, Herman J G, Guo M Z, Hooker C M, Schulick R D, Lillemoe K D, Cameron J L, Hruban R H, Maitra A, Yeo C J. Aberrant hypermethylation of tumor suppressor genes in pancreatic endocrine neoplasms. Ann Surg. 2003; 238: 423–31. [PUBMED], [INFOTRIEVE]
- Chan A O, Kim S G, Bedeir A, Issa J P, Hamilton S R, Rashid A. CpG island methylation in carcinoid and pancreatic endocrine tumors. Oncogene. 2003; 22: 924–34. [PUBMED], [INFOTRIEVE]